Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283967 · ClinicalTrials.gov registry record
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
A clinical trial of Tuberculosis, sponsored by University of Virginia.
- Completed
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT05283967: Completed study of Tuberculosis, sponsored by University of Virginia.
NCT05283967 is a study of Tuberculosis that has completed, run by University of Virginia. The registered enrollment target is 150 participants, below the 929-participant average among 29 other Tuberculosis trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283967, a study of Tuberculosis, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to generate receiver-operating-characteristic (ROC) curves for urine colorimetry to identify tuberculosis (TB) patients (children and adults) with low drug anti-TB drug exposures, which will define the diagnostic accuracy. The central hypothesis is that urine colorimetry will successfully identify patients with low anti-TB serum drug levels, and do so with diagnostic characteristics similar to other widely used tests in TB management.
Primary Outcome
Urine peak concentration (Cmax) of rifampin as determined by urine colorimetry
Conditions Studied
Interventions
- DIAGNOSTIC_TEST urine colorimetric assay
Study Locations (2)
New Jersey
- Rutgers, The State University of New Jersey - Newark
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2023-12-01 |
What the finished NCT05283967 record still lists
NCT05283967 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 929-participant average among 29 other Tuberculosis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 1 intervention - of which urine colorimetric assay is the first listed.
NCT05283967 reports a single indexed study location in New Jersey, Virginia.
Frequently Asked Questions
What is clinical trial NCT05283967 about?
NCT05283967 is a clinical study titled "Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults". The purpose of the study is to generate receiver-operating-characteristic (ROC) curves for urine colorimetry to identify tuberculosis (TB) patients (children and adults) with low drug anti-TB drug exposures, which will define the diagnostic accuracy. The central hypothesis is that urine colorimetry ...
What is the current status of trial NCT05283967?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2019-01-01. Estimated completion is 2023-12-01.
What conditions does trial NCT05283967 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT05283967?
The interventions under investigation include: urine colorimetric assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05283967?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283967 being conducted?
This trial has 2 study locations across New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05283967's enrollment target sits among peer trials
150 11th of 29 higher than 18 of 29 other Tuberculosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tuberculosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
RECRUITING
-
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
ACTIVE NOT RECRUITING
-
Gene Expression in HIV and Tuberculosis Co-infection
COMPLETED
-
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
COMPLETED · Phase 1
-
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI